• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Saccharomyces boulardii CNCM I-745 in different clinical conditions
【24h】

Saccharomyces boulardii CNCM I-745 in different clinical conditions

机译：布拉酵母菌CNCM I-745在不同的临床条件下

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Saccharomyces boulardii is a well-known probiotic worldwide, and there are numerous studies including experimental and clinical trials in children and adults by the use of S. boulardii. Areas covered: The objective of the present report is to provide an update on the evidence for the efficacy of S. boulardii CNCM I-745 in different clinical conditions. Saccharomyces boulardii is one of the best-studied probiotics in acute gastroenteritis (AGE) and is shown to be safe and to reduce the duration of diarrhea and hospitalization by about 1 day. Saccharomyces boulardii is one of the recommended probiotics for AGE in children by European Society of Paediatric Infectious Diseases and European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Saccharomyces boulardii is also a recommended probiotic for the prevention of antibioticassociated diarrhea (AAD), and a recent study showed promising results for the treatment of AAD in children. There is insufficient evidence to recommend the long-term use of S. boulardii in patients with irritable bowel syndrome. Although some clinical studies showed positive effects of S. boulardii on inflammation, there is no clinical evidence that S. boulardii is useful in inflammatory bowel disease. Saccharomyces boulardii could be used in patients needing Helicobacter pylori eradication because the S. boulardii improves compliance, decreases the side effects and moderately increases the eradication rate. There are new promising results (improving feeding tolerance, shorten the course of hyperbilirubinemia), but we do still not recommend the routine use of S. boulardii in newborns. Expert opinion: Saccharomyces boulardii CNCM I-745 is a good example for the statement that each probiotic needs to be taxonomically characterized and its efficacy and safety should be documented individually in different clinical settings.
机译：简介：布拉氏酵母是全世界著名的益生菌，并且有许多研究包括使用布拉氏链球菌在儿童和成人中进行的实验和临床试验。涵盖的领域：本报告的目的是提供有关布拉氏链球菌CNCM I-745在不同临床条件下疗效的证据的最新信息。布拉氏酵母是急性胃肠炎（AGE）中研究最好的益生菌之一，已被证明是安全的，可减少腹泻和住院时间约1天。糖酵母是欧洲儿科传染病学会和欧洲儿科胃肠病，肝病与营养学会（ESPGHAN）推荐的儿童AGE益生菌之一。酿酒酵母也是推荐的用于预防抗生素相关性腹泻（AAD）的益生菌，最近的一项研究表明，治疗儿童AAD的结果令人鼓舞。没有足够的证据推荐对肠易激综合症患者长期使用S. boulardii。尽管一些临床研究表明，布拉氏链球菌对炎症有积极作用，但没有临床证据表明布拉氏链球菌可用于炎症性肠病。布尔糖酵母可用于需要根除幽门螺杆菌的患者，因为布尔糖酵母可提高依从性，降低副作用并适度提高根除率。有新的有希望的结果（提高喂养耐受性，缩短高胆红素血症的病程），但我们仍不建议新生儿常规使用博拉氏链球菌。专家意见：酿酒酵母CNCM I-745是一个很好的例子，说明每种益生菌都需要进行分类学表征，其功效和安全性应在不同的临床环境中单独记录。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号